-
2 days ago | 
healio.com | Anthony DeFino |Arshad Khanani
Key takeaways: The meeting will take place June 21 in Las Vegas. Attendees will explore topics such as regulatory considerations for pivotal trial design and AI in imaging and clinical development. Clinical Trials at the Summit will be held Saturday, June 21, at Fontainebleau Las Vegas. The meeting will focus on the latest data in vitreoretinal care from ongoing clinical trials.
-
2 days ago | 
healio.com | Baruch D. Kuppermann |Anthony DeFino
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Baruch D. Kuppermann, MD, PhD, shares positivedata on the dexamethasone intravitreal implant for diabetic macular edema. The retrospective analysis included 167 patients with a suboptimal response to anti-VEGF treatment. “We either continued them on standard-of-care anti-VEGF injections or DEX implant was initiated,” he said.
-
5 days ago | 
healio.com | Anthony DeFino
Key Takeaways: Surgical intervention for pediatric pars planitis may be necessary if immunosuppression is ineffective. Know the complications of scleral buckling with or without pars plana vitrectomy. FORT LAUDERDALE, Fla. — In some cases of pediatric pars planitis, surgical intervention may be necessary, but possible complications must be considered, according to a speaker. At the Retina World Congress, Lisa J.
-
5 days ago | 
healio.com | Richard Small |Anthony DeFino
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Richard Small, CEO of Neurotech Pharmaceuticals, provides an update on Encelto for macular telangiectasia type 2. Ahead of the encapsulated cell therapy’s June launch following its FDA approval earlier this year, the company is educating retina specialists as well as the wider eye care community on macular telangiectasia and Encelto (revakinagene taroretcel-lwey).
-
6 days ago | 
healio.com | Dilraj S. Grewal |Anthony DeFino
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilraj S. Grewal, MD, FASRS,provides an update on the progress of therapies for noninfectious uveitis. While some therapies failed trials, others demonstrated promising results, including dazdotuftide (Tarsier Pharma), which reduced inflammation in patients with uveitis without raising IOP in a phase 3 trial.
-
1 week ago | 
healio.com | Justis P. Ehlers |Alex Young |Anthony DeFino
SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Justis P. Ehlers, MD, shares results from the phase 1 HELIOS study investigating OTX-TKI for the treatment of nonproliferative diabetic retinopathy. The study examined a single injection of OTX-TKI (axitinib intravitreal implant, Ocular Therapeutix) vs. sham in reducing intraretinal fluid.
-
1 week ago | 
healio.com | Alex Young |Eamon Dreisbach |Anthony DeFino
SALT LAKE CITY — In this Healio Video Perspective from the ARVO meeting, Paolo S. Silva, MD, discusses a study comparing ultrawide field red-green vs. red-green-blue imaging for determining the severity of diabetic retinopathy. “Based on our study of 95 eyes in 47 patients, we’ve seen that there is virtually no difference in the RG and RGB imaging devices in its ability to predict and identify the severity of retinopathy present in these eyes,” he said.
-
1 week ago | 
healio.com | Anthony DeFino
Key takeaways:The designation was supported by to-date results of the ongoing SPECTRA study in diabetic macular edema. The gene therapy is designed to offer sustained delivery of anti-VEGF after one injection. Editor’s note: This is a developing news story. Please check back soon for updates. The FDA granted regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema, according to a press release from 4D Molecular Therapeutics.
-
1 week ago | 
healio.com | Anthony DeFino
Patients in pain do not care about our clinical findings. They do not care about the pathophysiology underlying their pain. They do not care about the mechanism of action of the treatments we suggest. They do not care whether a treatment addresses the underlying cause(s) of their pain. They just want the pain to stop. Neurotrophic corneal pain (NCP) is the scourge of ocular surface disease (OSD) care, the bane of existence for doctors called upon to treat it.
-
1 week ago | 
healio.com | Anthony DeFino
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
